About Us
iRCM is an industry leader with innovative technology and an expert team. We are a complete Revenue Cycle Management solution that streamlines reimbursements and delivers remarkable results.
Contact Info
iRCM is an industry leader with innovative technology and an expert team. We are a complete Revenue Cycle Management solution that streamlines reimbursements and delivers remarkable results.
ICD-10-CM for a positive Cologuard® (mt-sDNA) result: R19.5 – Other fecal abnormalities (includes occult blood in feces/stools).
ICD-10-CM for the screening indication when ordering the stool test: Z12.11 – Encounter for screening for malignant neoplasm of colon (some payers also allow Z12.12 for rectum).
Follow-on colonoscopy after a positive stool-based test (U.S. federal policy): Still treated as screening under the “complete colorectal cancer screening” construct—append modifier KX to identify this context.
Sequence diagnoses per payer guidance (commonly Z12.11 ± R19.5) and first-list any definitive findings if present.
R19.5 Other fecal abnormalities is a billable, specific ICD-10-CM code that captures the clinical reality of an abnormal stool-based screening result.
Inclusion terms for R19.5 encompass occult blood in stool, consistent with the hemoglobin component of the sDNA-FIT algorithm when a result is positive.
Use R19.5 for the result-review encounter and as a secondary diagnosis on a follow-on procedure claim when the episode remains in a screening context.
Ordering the stool test for an average-risk patient: Use Z12.11 (screening for malignant neoplasm of colon) as the primary diagnosis on the lab claim; some payers accept Z12.12 when rectal screening is specified.
After a positive result, the patient now has an abnormal finding. For a problem-focused visit, first-list R19.5 and retain Z12.11 secondarily if your payer instructs you to maintain the screening context.
General ICD-10-CM principles support listing the condition chiefly responsible for the service first (i.e., the abnormal result), while Z-codes define the screening context.
Policy concept: In the U.S., a positive non-invasive stool-based test followed by colonoscopy is treated as a complete colorectal cancer screening.
Operational details:
Report the colonoscopy as screening and append modifier KX to identify that it follows a positive stool-based screening test.
Beneficiary cost-sharing is waived for this follow-on screening colonoscopy.
Screening frequency edits do not apply to the follow-on colonoscopy triggered by a positive test.
Coding pearls:
If a screening colonoscopy converts to a therapeutic procedure, append modifier PT to the applicable endoscopic CPT codes in addition to KX.
Diagnosis sequencing often uses Z12.11 and R19.5 for a normal follow-on colonoscopy; if pathology is found, list the definitive finding first.
Q1. What is the single best ICD-10 code for a positive Cologuard test?
A: R19.5 – Other fecal abnormalities. It encompasses the abnormal stool finding detected by sDNA-FIT (including occult blood).
Q2. Should Z12.11 be first-listed on the colonoscopy after a positive Cologuard?
A: Many payers accept Z12.11 listed with R19.5 when the follow-on colonoscopy is screening (identified with KX). If pathology is found, first list the definitive diagnosis. Confirm sequencing preferences with the payer.
Q3. Do routine screening frequency limits block the follow-on colonoscopy after a positive stool test?
A: No. Under the complete screening construct, the follow-on colonoscopy remains screening; routine limits do not apply, and cost-sharing is waived.
This guidance reflects the current ICD-10-CM code set (FY2026) and prevailing U.S. policy for stool-based colorectal cancer screening episodes. For commercial plans and Medicare Advantage, verify local policies for diagnosis orders and modifier requirements to avoid denials.
iRCM is an industry leader with innovative technology and an expert team. We are a complete Revenue Cycle Management solution that streamlines reimbursements and delivers remarkable results.
